

**RUTAN & TUCKER LLP**

Attorneys at Law

611 Anton Boulevard, 14th Floor

Costa Mesa California 92626-1998

Mailing Address: Post Office Box 1950, Costa Mesa, California 92628-1950

Telephone: 714.641.5100

Facsimile 714.546.9035

**FACSIMILE TRANSMISSION**

DATE: DECEMBER 10, 2002

TO:

Hard Copy to Follow via Mail: NO

NAME	FAX NO.	PHONE NO.
Howard Jr. Owens	<del>703-308-4556</del>	703-308-4624

FROM: Robert D Fish, Esq.

703 746-5125

RE:

OUR REF: 100848.213102US5	NUMBER OF PAGES, INCLUDING COVER: 2
10/094032 — 09/624555	
SPECIFIC MODULATION OF TH1/TH2 CYTOKINE EXPRESSION	
RIBAPHARM - ROBERT TAM	

MESSAGE:

**Informal Communication.****Please take a look at the draft claims.**

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AGENT RESPONSIBLE TO DELIVER THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

If there are problems receiving this Fax Transmittal please call 714.641.5100, Ext. 1235.

2022/XXX-  
000/00/00

## Draft claims (for 0/624855)

11. (added) A method of inhibiting HCV by growing a virus in an environment having lymphocytes which produce Type 1 and Type 2 cytokine responses, and adding ribavirin to the environment in a concentration which increases the Type 1 response and suppresses the Type 2 response.
12. (added) The method of claim 11 wherein the environment is a human patient, and ribavirin is administered to the human patient at no more than 800 mg/day.
13. (added) The method of claim 12 wherein ribavirin is administered at no more than 600 mg/day.
14. (added) The method of claim 13, further comprising administering interferon alpha to the patient.
15. (added) The method of claim 14, wherein the 600mg/day dosage is a full treatment dosage.
16. (added) A method of modulating Th1 and Th2 response in activated T cells of a human patient, comprising administering to the patient a combination of (a) an interferon alpha and (b) ribavirin in a treatment dosage to promote the Th1 response and suppresses the Th2 response.
17. (added) The method of claim 16 wherein the treatment dosage is no more than 800 mg/day.
18. (added) The method of claim 16 wherein the treatment dosage is no more than 600 mg/day.
19. (added) A method of treating a Hepatitis C Virus (HCV) infection in a patient comprising:  
receiving information that ribavirin may have little or no direct antiviral effect against the HCV virus;  
receiving information that ribavirin may be beneficial in treating the HCV infection within a dosage range based on a possible immunomodulatory effect; and  
encouraging a physician to administer the ribavirin to treat the HCV infection.
20. (added) The method of claim 19 further comprising encouraging the physician to administer the ribavirin in a combination therapy with an interferon.
21. (added) The method of claim 20 wherein the possible immunomodulatory effect is not clinically proven.